Projects / Programmes source: ARIS

Prognostic and predictive factors for response to treatment of breast cancer and other solid tumors

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B200  Biomedical sciences  Cytology, oncology, cancerology 
breast cancer, solid tumors, predictive factors, prognostic factors, proteases, sentinel node biopsy
Evaluation (rules)
source: COBISS
Researchers (14)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  16303  PhD Simona Borštnar  Oncology  Researcher  2004 - 2008  490 
2.  12179  PhD Tanja Čufer  Oncology  Head  2004 - 2008  774 
3.  23342  PhD Nebojša Glumac  Oncology  Researcher  2004  41 
4.  29971  Breda Kosmač    Technical associate  2008 
5.  12224  PhD Borut Kragelj  Oncology  Researcher  2004 - 2008  81 
6.  26230  Petra Nussdorfer    Technical associate  2005 - 2007  11 
7.  13541  PhD Janja Ocvirk  Oncology  Researcher  2004 - 2008  819 
8.  16280  PhD Boris Sedmak  Medical sciences  Researcher  2004 - 2008  78 
9.  12250  PhD Marko Snoj  Oncology  Researcher  2004 - 2008  195 
10.  13157  PhD Breda Škrbinc  Oncology  Researcher  2004 - 2008  104 
11.  01324  PhD Iztok Takač  Human reproduction  Researcher  2004 - 2008  909 
12.  07195  PhD Ivan Vrhovec  Oncology  Researcher  2004 - 2008  116 
13.  29972  Marija Zalar    Technical associate  2008 
14.  24571  PhD Ivana Žagar  Oncology  Researcher  2005 - 2008  198 
Organisations (3)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,390 
2.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  76,701 
3.  0334  University Medical Centre Maribor  Maribor  5054150000  22,594 
The aim of our research programme is to study the best treatment options for different cancers. With the developement of new treatments there is also some emphasis on the research of biological cancer characteristics, which could enable us to identify those patients, that would benefit most from a certain treatment, as early as while setting the diagnosis. In the frame of this study we will research the pronostic factors for the course of the disease and for response to certain treatments, in patients with breast cancer, ventricular cancer and bladder cancer. We intend to research the predictive value of serine protease uPA and its inhibitors PAI-1 and PAI-2 for response to systemic treatment in adjuvant and metastatic setting of breast cancer. The efficacy and toxicity of sentinel node biopsy, compared to complete axilliary dissection and/or radiotherapy of axilla, in patients with operable breast cancer, will be evaluated. In metastatic ventricular cancer we will compare the efficacy and toxicity of chemotherapeutic schedules including capecitabine with those, routinelly used, including 5-fluorouracil. Since capecitabine is a cytostatic drug, which is only metabolised into the active substance 5-fluorouracil once it enters the tumor, we expect this treatment to provide a better efficacy as well as lower toxicity. In muscle invasive bladder cancer we will evaluate the efficacy and toxicity of bladder salvage treatment with transurethral resection, chemotherapy and radiotherapy with regard to tumor and patient characteristics. We will also research the efficacy and toxicity of concurrent radiotherapy and chemotherapy with gemcitabine.
Significance for science
New discoveries in molecular oncology of cancer and translation of this knowledge into diagnosis and treatment of various cancers, is one of the most important fields of cancer research nowadays. By researching molecular tumor markers in different solid tumors as well as lymphomas and by evaluating their prognostic and predictive value for response to systemic therapy our new findings will contribute to a better understanding of molecular oncology and improved individualized tailored systemic therapy of cancer.
Significance for the country
Cancer is the major public health issue in whole developed world. With the ageing of the population, a sustained increase in cancer incidence can also be foreseen. Research and new findings in the field of molecular oncology as well as transfer of this knowledge into routine clinical practice are of utmost importance for good cancer control worldwide. Our research programme is structured to allow for research of new prognostic and predictive molecular tumor markers and allows for a rapid transfer of knowledge into routine clinical practice in Slovenia. The importance of our research is based on the fact that more than 10.000 new cancer patients are diagnosed in Slovenia each year and the prevalence of the disease is already around 60.000.
Most important scientific results Final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Final report, complete report on dLib.si
Views history